Amarin Gets Expedited Appeal in Patent Case Over Vascepa Copies

Written legal arguments in Amarin’s appeal are due through June 26 and oral arguments “will be placed on the next available oral argument calendar once briefing is complete,” U.S. Court of Appeals for the Federal Circuit ruled.

• Hikma and Dr. Reddy’sdidn’t object to Amarin’s request to expedite the appeal
• Amarin is challenging a March trial court ruling that invalidated its patents on the heart treatment Vascepa
• The ruling opened the door to low-cost versions of the drug
  • Hikma and Dr. Reddy’s don’t have FDA approval to sell a generic, according to Amarin’s April 22 filing with the court
• NOTE: ...